JP6632974B2 - フェノール可溶性モジュリン、δ毒素、スーパー抗原に由来するトキソイドペプチド、およびその融合物 - Google Patents

フェノール可溶性モジュリン、δ毒素、スーパー抗原に由来するトキソイドペプチド、およびその融合物 Download PDF

Info

Publication number
JP6632974B2
JP6632974B2 JP2016521549A JP2016521549A JP6632974B2 JP 6632974 B2 JP6632974 B2 JP 6632974B2 JP 2016521549 A JP2016521549 A JP 2016521549A JP 2016521549 A JP2016521549 A JP 2016521549A JP 6632974 B2 JP6632974 B2 JP 6632974B2
Authority
JP
Japan
Prior art keywords
seq
oligopeptide
amino acid
peptide
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016521549A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016522259A (ja
JP2016522259A5 (enExample
Inventor
モハマド ジャバド アマン
モハマド ジャバド アマン
ラジャン プラサド アディカリ
ラジャン プラサド アディカリ
セルゲイ シュレーニン
セルゲイ シュレーニン
フレデリック ウェイン ホルツバーグ
フレデリック ウェイン ホルツバーグ
ハティス カラウズム
ハティス カラウズム
Original Assignee
インテグレイテッド バイオセラピューティクス，インコーポレイテッド
インテグレイテッド バイオセラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52105236&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6632974(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by インテグレイテッド バイオセラピューティクス，インコーポレイテッド, インテグレイテッド バイオセラピューティクス，インコーポレイテッド filed Critical インテグレイテッド バイオセラピューティクス，インコーポレイテッド
Publication of JP2016522259A publication Critical patent/JP2016522259A/ja
Publication of JP2016522259A5 publication Critical patent/JP2016522259A5/ja
Application granted granted Critical
Publication of JP6632974B2 publication Critical patent/JP6632974B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2016521549A 2013-06-19 2014-06-18 フェノール可溶性モジュリン、δ毒素、スーパー抗原に由来するトキソイドペプチド、およびその融合物 Active JP6632974B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361836959P 2013-06-19 2013-06-19
US61/836,959 2013-06-19
PCT/US2014/042999 WO2014205111A1 (en) 2013-06-19 2014-06-18 Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof

Publications (3)

Publication Number Publication Date
JP2016522259A JP2016522259A (ja) 2016-07-28
JP2016522259A5 JP2016522259A5 (enExample) 2017-07-27
JP6632974B2 true JP6632974B2 (ja) 2020-01-22

Family

ID=52105236

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016521549A Active JP6632974B2 (ja) 2013-06-19 2014-06-18 フェノール可溶性モジュリン、δ毒素、スーパー抗原に由来するトキソイドペプチド、およびその融合物

Country Status (7)

Country Link
US (2) US9815872B2 (enExample)
EP (1) EP3010535B1 (enExample)
JP (1) JP6632974B2 (enExample)
CA (1) CA2916231C (enExample)
DK (1) DK3010535T3 (enExample)
PT (1) PT3010535T (enExample)
WO (1) WO2014205111A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2916231C (en) 2013-06-19 2024-02-06 Integrated Biotherapeutics, Inc. Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof
WO2018037408A1 (en) * 2016-08-22 2018-03-01 Technion Research & Development Foundation Limited Antimicrobial peptides and uses thereof
EP3532618A4 (en) * 2016-10-27 2020-05-20 MedImmune, LLC SIGNAL POLYPEPTIDES FOR IMPROVED PROTEIN SECRETION
CN107224575B (zh) * 2017-03-06 2018-11-09 浙江海隆生物科技有限公司 奶牛金黄色葡萄球菌乳房炎亚单位疫苗的组合物及其制备方法和应用
MX2020001046A (es) 2017-07-27 2020-08-06 Integrated Biotherapeutic Vaccines Inc Composicion inmunogenica que comprende un peptido de fusion derivado de toxoides de superantigenos.
CN115427433A (zh) 2020-12-18 2022-12-02 生物医学研究及生物制品公司 保护性葡萄球菌外毒素疫苗
US12370235B2 (en) 2021-03-04 2025-07-29 University Of Saskatchewan Synthetic, non-natural antimicrobial peptides inspired by Staphylococcus auricularis delta toxin
GR1010289B (el) * 2021-04-27 2022-08-29 Integrated Biotherapeutic Vaccines, Inc., Τοξοειδη πεπτιδια που προερχονται απο διαλυτη σε φαινολη μοδουλινη, τοξινη δελτα, υπεραντιγονα και συντηξεις αυτων
CN113234125B (zh) * 2021-05-10 2022-12-06 华东理工大学 自组装多肽、多肽水凝胶及其制备方法和用途
WO2023227563A1 (en) 2022-05-23 2023-11-30 Biomedizinische Forschung & Bio-Produkte AG Protective staphylococcal exotoxin vaccine
WO2023247747A1 (en) 2022-06-23 2023-12-28 Biomedizinische Forschung & Bio-Produkte AG Protective staphylococcal exotoxin vaccine

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6593114B1 (en) * 1996-01-05 2003-07-15 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6713284B2 (en) 1997-06-25 2004-03-30 The United States Of America As Represented By The Secretary Of The Army Bacterial superantigen vaccines
US7087235B2 (en) * 1997-06-25 2006-08-08 The United States Of America As Represented By The Secretary Of The Army Fusion protein of streptococcal pyrogenic exotoxins
AU761021B2 (en) * 1998-07-10 2003-05-29 U.S. Medical Research Institute Of Infectious Diseases Department Of The Army Vaccine against staphylococcus intoxication
GB0118155D0 (en) 2001-07-25 2001-09-19 Lorantis Ltd Superantigen
NZ561879A (en) * 2003-03-07 2009-05-31 Wyeth Corp Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
US20050008633A1 (en) 2003-05-19 2005-01-13 Advanced Inhalation Research Inc. Chemical and physical modulators of bioavailability of inhaled compositions
US7754225B2 (en) 2006-07-20 2010-07-13 Glaxosmithkline Biologicals S.A. Method of protecting against staphylococcal infection
WO2008154101A1 (en) * 2007-06-06 2008-12-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Psm peptides as vaccine targets against methicillin-resistant staphylococcus aureus
KR20100072228A (ko) * 2007-08-31 2010-06-30 유니버시티 오브 시카고 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물
AU2012214677B2 (en) 2011-02-08 2016-11-10 Abvacc, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides
CN103561762A (zh) * 2011-03-16 2014-02-05 明尼苏达大学董事会 诱导针对葡萄球菌属中细菌的免疫应答的组合物和方法
CA2857666C (en) 2011-12-02 2020-08-11 Integrated Biotherapeutics, Inc. Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides
CA2916231C (en) 2013-06-19 2024-02-06 Integrated Biotherapeutics, Inc. Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof

Also Published As

Publication number Publication date
PT3010535T (pt) 2020-07-03
US20180148482A1 (en) 2018-05-31
DK3010535T3 (da) 2020-11-30
US20160185829A1 (en) 2016-06-30
JP2016522259A (ja) 2016-07-28
US10174085B2 (en) 2019-01-08
US9815872B2 (en) 2017-11-14
EP3010535A4 (en) 2017-03-01
EP3010535B1 (en) 2019-08-14
CA2916231C (en) 2024-02-06
CA2916231A1 (en) 2014-12-24
EP3010535A1 (en) 2016-04-27
WO2014205111A1 (en) 2014-12-24

Similar Documents

Publication Publication Date Title
US10174085B2 (en) Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof
AU2012214677B2 (en) Immunogenic composition comprising alpha-hemolysin oligopeptides
CA2857666C (en) Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides
US11421021B2 (en) Immunogenic compositions comprising Staphylococcus aureus leukocidin LukA and LukB derived polypeptides
WO2005079315A2 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
US11826412B2 (en) Immunogenic composition comprising a fusion peptide derived from superantigen toxoids
US20180141981A1 (en) Immunogenic composition comprising engineered alpha-hemolysin oligopeptides
GR1010289B (el) Τοξοειδη πεπτιδια που προερχονται απο διαλυτη σε φαινολη μοδουλινη, τοξινη δελτα, υπεραντιγονα και συντηξεις αυτων
CA3066450C (en) Immunogenic compositions comprising staphylococcus aureus leukocidin luka and lukb derived polypeptides
NZ626762B2 (en) Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180517

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190604

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191211

R150 Certificate of patent or registration of utility model

Ref document number: 6632974

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250